Internal Reference Number: FOI_7006
Date Request Received: 06/02/2023 00:00:00
Date Request Replied To: 01/03/2023 00:00:00
This response was sent via: By Email
Request Summary: Biologic medicines in gastroenterology
Request Category: Companies
Question Number 1: How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Filgotinib • Golimumab • Infliximab - Remicade • Infliximab Biosimilar • Ozanimod • Tofacitinib • Upadacitinib • Ustekinumab • Vedolizumab | |
Answer To Question 1: Adalimumab (Humira) - 16 Adalimumab (Biosimilar) - 119 Filgotinib - 8 Golimumab - <5 Infliximab (Remicade) - 22 Infliximab (Biosimilar) - 246 Toficitinib - <5 Ustekinumab - 93 Vedolizumab - 76 | |
Question Number 2: If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Crohn's Disease ONLY with the following biologic drugs: • Adalimumab - Humira • Adalimumab Biosimilar • Golimumab • Infliximab - Remicade • Infliximab Biosimilar • Upadacitinib • Ustekinumab • Vedolizumab | |
Answer To Question 2: Adalimumab (Humira) - 7 Adalimumab (Biosimilar) -51 Golimumab - 0 Infliximab (Remicade) - 8 Infliximab (Biosimilar) - 89 Upadacitinib - 0 Ustekinumab - 41 Vedolizumab - 21 | |
To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.